CR11239A - Peptido antimicrobiano composiciones y metodos de uso - Google Patents

Peptido antimicrobiano composiciones y metodos de uso

Info

Publication number
CR11239A
CR11239A CR11239A CR11239A CR11239A CR 11239 A CR11239 A CR 11239A CR 11239 A CR11239 A CR 11239A CR 11239 A CR11239 A CR 11239A CR 11239 A CR11239 A CR 11239A
Authority
CR
Costa Rica
Prior art keywords
methods
antimicrobial peptide
peptide compositions
antimicrobial
fungi
Prior art date
Application number
CR11239A
Other languages
English (en)
Spanish (es)
Inventor
Hongran Fan Stone
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of CR11239A publication Critical patent/CR11239A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CR11239A 2007-07-26 2010-01-27 Peptido antimicrobiano composiciones y metodos de uso CR11239A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95205907P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
CR11239A true CR11239A (es) 2010-06-29

Family

ID=40281862

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11239A CR11239A (es) 2007-07-26 2010-01-27 Peptido antimicrobiano composiciones y metodos de uso

Country Status (24)

Country Link
US (1) US8623811B2 (OSRAM)
EP (3) EP3741380A1 (OSRAM)
JP (5) JP5401457B2 (OSRAM)
KR (4) KR101717275B1 (OSRAM)
CN (2) CN102872447B (OSRAM)
AU (1) AU2008278593B2 (OSRAM)
BR (3) BR122019000258B1 (OSRAM)
CA (1) CA2694046C (OSRAM)
CO (1) CO6260098A2 (OSRAM)
CR (1) CR11239A (OSRAM)
CY (2) CY1118503T1 (OSRAM)
DK (2) DK3120862T3 (OSRAM)
ES (2) ES2805225T3 (OSRAM)
HR (1) HRP20161722T1 (OSRAM)
HU (1) HUE031136T2 (OSRAM)
IL (3) IL203173A (OSRAM)
LT (1) LT2178549T (OSRAM)
MX (1) MX2010000916A (OSRAM)
NZ (1) NZ582459A (OSRAM)
PL (1) PL2178549T3 (OSRAM)
PT (2) PT2178549T (OSRAM)
SG (1) SG188128A1 (OSRAM)
SI (1) SI2178549T1 (OSRAM)
WO (1) WO2009015385A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080226551A1 (en) * 2006-12-29 2008-09-18 Revance Therapeutics, Inc. Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides
PT2178549T (pt) * 2007-07-26 2016-12-20 Revance Therapeutics Inc Péptido antimicrobiano e suas composições
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US8198034B2 (en) 2008-03-14 2012-06-12 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
NO2379104T3 (OSRAM) 2008-12-31 2018-07-28
CA2757449A1 (en) * 2009-04-01 2010-10-07 Revance Therapeutics, Inc. Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
AU2010259986B2 (en) 2009-06-10 2015-04-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
KR101975051B1 (ko) 2009-06-25 2019-05-03 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
FR2997304B1 (fr) 2012-10-26 2017-07-07 Isp Investments Inc Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
BR112018005316A2 (pt) 2015-09-17 2018-12-11 Contrafect Corporation ?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo?
US10105381B2 (en) * 2016-05-23 2018-10-23 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10144767B2 (en) * 2016-08-18 2018-12-04 Board Of Regents Of The University Of Nebraska Anti-microbial peptides and coatings
MX2019005833A (es) * 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
CN107556374B (zh) * 2017-08-30 2020-02-07 四川大学 唾液富脯蛋白仿生防龋功能多肽、其衍生物和盐及其应用
CN107353334B (zh) * 2017-08-30 2020-02-07 四川大学 基于唾液富酪蛋白的仿生防龋多肽、其衍生物和盐及应用
JP7266202B2 (ja) * 2018-02-19 2023-04-28 株式会社ファンケル 化粧料及び抗炎症剤
CA3179706A1 (en) * 2020-04-08 2021-10-14 Amicrobe, Inc. Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections
WO2025059665A1 (en) 2023-09-15 2025-03-20 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
WO2025072381A1 (en) 2023-09-25 2025-04-03 Revance Therapeutics, Inc. Methods for determining influence of carrier peptide on the binding of a therapeutic protein to a cell membrane

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
AU4037793A (en) 1992-04-23 1993-11-29 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
DE656950T1 (de) 1992-08-21 1996-03-14 Biogen Inc Tat-derivate transport polypeptide.
WO1995011038A1 (en) * 1993-10-22 1995-04-27 Allelix Biopharmaceuticals Inc. Treatment of cytomegalovirus infection
EP1790352B1 (en) 1993-12-28 2008-07-09 Allergan, Inc. Use of botulinum toxin for the manufacture of a medicament for reducing low back pain
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
JP3860838B2 (ja) 1995-08-23 2006-12-20 ユニバーシティー オブ ブリティッシュ コロンビア 抗微生物性陽イオン性ペプチドおよびそのスクリーニング方法
US6043218A (en) * 1996-10-22 2000-03-28 Medical University Of South Carolina Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US6221355B1 (en) 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
JP2002508187A (ja) 1997-12-12 2002-03-19 オニックス ファーマシューティカルズ，インコーポレイティド Ｐ５３＋新生細胞の選択的殺死及び診断
ATE314859T1 (de) 1998-10-27 2006-02-15 Mayo Foundation Botulinumtoxine zur verstärkung der wundheilung
JP2002531113A (ja) 1998-12-10 2002-09-24 ワシントン大学 蛋白質の形質導入システムおよびその使用法
EP1140021B1 (en) 1998-12-23 2004-08-04 Idea Ag Improved formulation for topical non-invasive application in vivo
US7056656B1 (en) 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US20030236214A1 (en) 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US7008924B1 (en) 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20030215412A1 (en) 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
ES2617692T3 (es) 2000-07-21 2017-06-19 Revance Therapeutics, Inc. Sistemas de transporte de agentes biológicos de múltiples componentes
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
WO2002065986A2 (en) 2001-02-16 2002-08-29 Cellgate, Inc. Transporters comprising spaced arginine moieties
AU2002305539A1 (en) * 2001-05-09 2002-11-18 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7169814B2 (en) 2001-12-11 2007-01-30 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
AU2003216389A1 (en) 2002-02-21 2003-09-09 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP4154218B2 (ja) * 2002-11-27 2008-09-24 寛紀 高麗 新規抗菌性ポリペプチドとその利用
IL153557A0 (en) * 2002-12-19 2003-07-06 Yitzchak Hillman Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
US20060115480A1 (en) * 2002-12-19 2006-06-01 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
WO2004069182A2 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
WO2004084805A2 (en) 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
ZA200602754B (en) * 2003-09-12 2007-06-27 Univ British Columbia Effectors of innate immunity determination
JP2005120050A (ja) * 2003-10-20 2005-05-12 Toagosei Co Ltd 新規抗菌性ペプチドとその利用
EP2656859B1 (en) 2004-03-03 2015-10-21 ReVance Therapeutics, Inc. Topical application and transdermal delivery of botulinum toxins
MXPA06009897A (es) 2004-03-03 2008-02-07 Revance Therapeutics Inc Composiciones y metodos para el diagnostico topico y el transporte terapeutico.
BRPI0514420B1 (pt) * 2004-08-18 2022-05-17 Novabiotics Limited Peptídeo, ou um sal farmaceuticamente aceitável do mesmo, e, uso de um peptídeo
EP1824976A4 (en) 2004-11-12 2008-07-09 Univ British Columbia ANTIMICROBIAL PEPTIDES
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
EP1661912A1 (en) 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
JP4730584B2 (ja) * 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
JP2006238751A (ja) * 2005-03-02 2006-09-14 Toagosei Co Ltd ベロ毒素結合性を有する抗菌ペプチド及びその利用
EP1856139B1 (en) 2005-03-03 2011-04-27 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
MX2007010673A (es) 2005-03-03 2008-04-07 Revance Therapeutics Inc Composiciones y metodos para la aplicacion topica y el suministro transdermico de toxinas botulinicas.
JP5388568B2 (ja) 2005-03-30 2014-01-15 ルバンス セラピュティックス インク． ざ瘡を治療するための組成物及び方法
BRPI0618753A2 (pt) 2005-11-17 2011-09-13 Revance Therapeutics Inc composição para liberação transdérmica de toxina botulìnica e método de administração
WO2008082889A2 (en) 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
US20080226551A1 (en) 2006-12-29 2008-09-18 Revance Therapeutics, Inc. Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides
PT2178549T (pt) * 2007-07-26 2016-12-20 Revance Therapeutics Inc Péptido antimicrobiano e suas composições
NO2379104T3 (OSRAM) 2008-12-31 2018-07-28

Also Published As

Publication number Publication date
IL223784A (en) 2015-02-26
IL203173A (en) 2014-12-31
CY1123176T1 (el) 2021-10-29
LT2178549T (lt) 2017-01-25
EP3120862A1 (en) 2017-01-25
AU2008278593A2 (en) 2011-05-12
AU2008278593B2 (en) 2015-04-09
DK2178549T3 (en) 2017-01-09
JP5401457B2 (ja) 2014-01-29
KR101722038B1 (ko) 2017-04-03
AU2008278593A1 (en) 2009-01-29
JP2019006791A (ja) 2019-01-17
CA2694046C (en) 2023-09-12
EP2178549B1 (en) 2016-09-14
US8623811B2 (en) 2014-01-07
KR20150090268A (ko) 2015-08-05
EP2178549A4 (en) 2014-02-19
CN101842107A (zh) 2010-09-22
JP5965884B2 (ja) 2016-08-10
BR122019000266B1 (pt) 2021-09-14
WO2009015385A1 (en) 2009-01-29
PT3120862T (pt) 2020-06-25
SI2178549T1 (sl) 2017-08-31
BR122019000258B1 (pt) 2021-09-14
PT2178549T (pt) 2016-12-20
JP2014076993A (ja) 2014-05-01
KR101717275B1 (ko) 2017-03-16
CN102872447B (zh) 2015-09-30
CY1118503T1 (el) 2017-07-12
CA2694046A1 (en) 2009-01-29
NZ582459A (en) 2012-05-25
KR20180031824A (ko) 2018-03-28
BRPI0813627A2 (pt) 2014-12-23
KR102088949B1 (ko) 2020-03-13
EP3741380A1 (en) 2020-11-25
JP2010534684A (ja) 2010-11-11
IL223785A (en) 2015-02-26
MX2010000916A (es) 2010-06-02
ES2805225T3 (es) 2021-02-11
ES2609914T3 (es) 2017-04-25
CN102872447A (zh) 2013-01-16
SG188128A1 (en) 2013-03-28
KR20100047867A (ko) 2010-05-10
KR20170016031A (ko) 2017-02-10
US20100215591A1 (en) 2010-08-26
PL2178549T3 (pl) 2017-03-31
HK1180237A1 (zh) 2013-10-18
CN101842107B (zh) 2014-04-23
EP3120862B1 (en) 2020-04-29
BRPI0813627B1 (pt) 2021-09-14
DK3120862T3 (da) 2020-06-22
HRP20161722T1 (hr) 2017-02-10
HUE031136T2 (en) 2017-07-28
EP2178549A1 (en) 2010-04-28
JP2020169190A (ja) 2020-10-15
CO6260098A2 (es) 2011-03-22
JP6722241B2 (ja) 2020-07-15
JP2017002057A (ja) 2017-01-05

Similar Documents

Publication Publication Date Title
CR11239A (es) Peptido antimicrobiano composiciones y metodos de uso
GT201300152A (es) Amidas aminoindanes con una alta actividad fungicida y sus composiciones fitosanitarias
PH12017502300A1 (en) Pesticidal compositions and processes related thereto
GEP20156230B (en) Forms of rifaximin and usage thereof
UY39963A (es) Composiciones herbicidas a base de carbamoíltriazolinona y métodos de uso
UY32659A (es) Pirazinilpirazoles
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
EA201500582A1 (ru) Тройные фунгицидные смеси
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
NZ618571A (en) Peptides and their use
MX2013009252A (es) Composiciones y procesos relacionados con los mismos plaguicidas.
CR11259A (es) Bromhidrato de bupropion y aplicaciones terapueticas
MX2013011548A (es) Formulaciones de agente de curtido particulado sólido.
CL2008003632A1 (es) Uso de hidroxidos de guanidinio polimericos para combatir microorganismos no deseados; procedimiento para combatir hongos fitopatogenos; combinaciones de principio activo que comprenden al menos un hidroxido de guanidinio.
UY34360A (es) ?compuestos de tipo bisamida con actividad insecticida, procesos e intermediarios?
PA8784301A1 (es) Oxazolidinonas sustituidas y su uso
SV2006002290A (es) Nonadepsipeptidos acilados ii ref. bhc041327-sv
WO2012148720A3 (en) Anti-microbial peptides and methods of use thereof
MX2015008373A (es) Peptidos antimicrobianos, composiciones que los comprende y usos.
GT201200277A (es) Derivados de ditiinopiridazindiona
MX2013003156A (es) Composiciones de dibromomalonamida y su uso como biocida.
MEP31908A (en) Peptide compound with biological activity, its preparation and its application
ES2422680T3 (es) Composición fungicida agrícola u hortícola y su uso para el control de fitopatógenos
MX367893B (es) Odorante de salvia.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)